Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2626 - A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study


11 Sep 2017


Poster display session


Clinical Research


Markus Joerger


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


M. Joerger1, R.A. Soo2, B.C. Cho3, A. Navarro4, C.M. Sayehli5, H. Richly6, D. Tai7, D. Kim8, J. Wolf9, P. Cassier10, S. Bender11, P. Ellinghaus11, S. Ince12, P. Rajagopalan13, M. Ocker14, M. Schuler6

Author affiliations

  • 1 Medical Oncology & Hematology, Cantonal Hospital, 9007 - St. Gallen/CH
  • 2 Department Of Haematology-oncology, National University Hospital, 119074 - Singapore/SG
  • 3 Department Of Internal Medicine, Yonsei Cancer Center, Seoul/KR
  • 4 Deparment Of Oncology, University Hospital Vall d’Hebron, 08035 - Barcelona/ES
  • 5 Early Clinical Trial Unit, University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), 97080 - Würzburg/DE
  • 6 Department Of Medical Oncology, West German Cancer Center, University Hospital Essen, 45122 - Essen/DE
  • 7 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 8 Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 9 Medical Oncology, CIO ∙ Cancer Center Cologne, Köln/DE
  • 10 Département D'oncologie Médicale Adulte, Centre Léon Bérard, 69008 - Lyon/FR
  • 11 Biomarker Research, Bayer AG, 42113 - Wuppertal/DE
  • 12 Project Management, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 13 Biostatistics, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 14 Biomarker Strategy, Bayer AG, 13353 - Berlin/DE


Abstract 2626


Altered FGFR signaling is a potential target for anticancer therapy. Rogaratinib (BAY1163877) is an oral inhibitor of FGFRs 1-4. Screening for patients based on tumor FGFR1-3 mRNA overexpression, we reported in a phase I study that selected urothelial carcinoma patients were highly sensitive to rogaratinib treatment (NCT01976741; Joerger et al, ESMO 2016). Here we further identify patients sensitive to rogaratinib with malignancies not previously identified as being driven by FGFRs.


Subjects with treatment-refractory advanced or metastatic solid tumors were screened for high FGFR1-3 mRNA expression levels by RNA in situ hybridization (RNAscope®; Advanced Cell Diagnostics, Inc., Newark, CA) and Nanostring® assay (NanoString Technologies, Inc., Seattle, WA) from fresh or archival tumor specimens. FGFR-positive patients were treated with 800 mg BID on a continuous 21-day cycle. Responses were assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.


More than 500 patient biopsies were screened for FGFR1-3 mRNA levels. Seventy two FGFR-positive patients were treated with rogaratinib, with 63 evaluable for response. Clinical responses were observed in tumor types not previously associated with FGFR alterations, including a partial remission (PR) in a patient with a FGFR1 mRNA-positive adenoid cystic carcinoma of the tongue and a PR in a FGFR3 mRNA-positive head and neck squamous cell carcinoma patient. Long-lasting stable disease with tumor shrinkage was also seen in patients with a) FGFR3 mRNA-positive gastric cancer, b) FGFR3 mRNA-positive lung squamous cell carcinoma c) FGFR3 mRNA-positive lung adenocarcinoma, d) FGFR2 mRNA-positive breast cancer and e) FGFR1 mRNA-positive hemangioendothelioma with complete disappearance of edema over 18 months.


Patient selection for treatment with rogaratinib based on quantification of FGFR1-3 mRNA isoforms in all tumor types irrespective of underlying data on DNA alterations is feasible and yields clinically meaningful responses in tumor types not been previously associated with altered FGFR signaling.

Clinical trial identification


Legal entity responsible for the study

Bayer AG


Bayer AG


S. Bender, P. Ellinghaus, M. Ocker: Employment: Bayer AG. S. Ince, P. Rajagopalan: Employment: Bayer HealthCare Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.